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Abstract
Background Cancer cachexia is a complex syndrome
associated with multiple metabolic abnormalities. Insulin
resistance is present in many cancer patients and may
be one mechanism through which muscle wasting
occurs.
Methods and results The present review examines evidence
in support of a role for insulin resistance in the develop-
ment of muscle wasting during cancer cachexia and
identifies areas for future research. Patients suffering from
cancer cachexia tend to exhibit insulin resistance and
improvements in insulin resistance have the potential to
improve cachexia symptoms. In addition, evidence suggests
that insulin resistance may occur prior to the onset of
cachexia symptoms.
Conclusions Further investigation of the role of insulin
resistance in cancer cachexia is needed. The use of
translational research in this area is strongly encouraged,
and has important implications for clinical research and the
treatment and prevention of cancer cachexia.
Keywords Insulin resistance.Muscle wasting.Cancer
cachexia.Animal models
1 Introduction
Individuals with cancer commonly experience anorexia,
weight loss, and wasting of muscle and adipose tissue [1,
2]. These symptoms are also accompanied by a number of
metabolic abnormalities, including alterations in carbohy-
drate, protein, and lipid metabolism, and insulin resistance
[3, 4]. This syndrome, known as cachexia, greatly decreases
the quality of life among patients, reducing survival time,
and psychological and physical health [5]. In addition,
cachectic cancer patients often display more negative side
effects during chemotherapy [6, 7]. Some estimates suggest
that up to 80% of cancer patients exhibit some degree of
cachexia [6, 8, 9], making this a clinically relevant
syndrome for which the cause is currently unknown.
While weight loss is obvious in the outward appearance,
the specific loss of muscle mass may be most detrimental to
patient health and outcomes. As skeletal muscle mass
decreases, strength, energy, and quality of life also decline
sharply [5, 10]. Muscle loss is associated with decreased
mobility and independence, as well as increased rates of
hospitalization [10]. In many cases, it is the loss of muscle
mass, and not explicit body weight, that results in the final
decline in functioning and death in cachectic cancer
patients [5, 10].
Despite the devastating toll this syndrome has on
patients, current treatment strategies are inadequate. In
addition, the reversal of cachexia symptoms is difficult
once they appear [10], making early intervention and
prevention efforts key. Identifying those at risk for
cachexia, however, is difficult. It is currently unknown
why cancer cachexia occurs in some patients but not others,
and across varying types of tumors. Our understanding of
which factors are present prior to cachexia development,
and which are only a result of cachexia, is poor. Thus, early
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prognosis in many patients. Improvements in weight loss
and appetite can be obtained through a number of treat-
ments, including progesterones, glucocorticoids, and nutri-
tional supplementation [11]. Unfortunately, gains in body
weight are typically due to increased body fat and water
retention, and such gains do not last [11]. While advances
have been made in the treatment of muscle wasting
associated with other chronic diseases, including congestive
heart failure (CHF) and chronic obstructive pulmonary
disease, the prevention of muscle wasting in individuals
with cancer remains illusive.
Given the metabolic nature of cancer cachexia, the study
of its mechanisms ought to include an evaluation of the
influence of metabolic pathways. In particular, the presence
of insulin resistance in many cancer patients and animal
models of cancer cachexia warrants significant attention.
For the purposes of the present investigation, insulin
resistance is defined as a significant decrease in insulin
sensitivity. Insulin sensitivity is commonly measured via a
glucose tolerance test, in which a standard dose of glucose
is administered and the ability of endogenous insulin to
regulate blood glucose levels is monitored. Similarly,
insulin tolerance testing has been utilized for this purpose,
with the glucose response to a standard insulin dose
measured. While insulin acts on many systems beyond
those regulating of glucose homeostasis, such testing is
o f t e nr e l i e du p o na sam e a s u r eo fp e r i p h e r a li n s u l i n
sensitivity and insulin resistance in health and disease.
2 Insulin and the control of skeletal muscle mass
Insulin is the main hormone responsible for the control of
muscle proteolysis [12]. An increase in the availability of
glucose in the blood, such as when a meal is consumed,
triggers a release of insulin from pancreatic β cells. This
increase in endogenous insulin concentration decreases
circulating blood glucose levels and suppresses proteolysis
[12]. Similarly, the infusion of physiologically relevant
doses of insulin can produce a decrease in skeletal muscle
protein degradation, as measured by the appearance of
amino acids in local circulation, without any effect on
blood glucose levels [13] or protein synthesis [14]. An
infusion of a higher dose of insulin decreases blood glucose
levels, with no further effect on protein degradation. Thus,
insulin has the potential to regulate skeletal muscle mass
within a limited physiological range of concentrations,
primarily through alterations in protein degradation. When
insulin sensitivity is compromised, skeletal muscle mass is
adversely affected. Both human and animal studies have
demonstrated that insulin resistance is present in other
catabolic diseases, such as diabetes mellitus, AIDS, and
CHF, in which significant muscle wasting is observed [15–
22].
The mechanism through which muscle wasting occurs in
cancer cachexia is the same as that which occurs in other
catabolic diseases. Though a number of pathways contrib-
uting to muscle protein degradation may be affected in
cancer cachexia, evidence suggests that the ATP-dependent
ubiquitin–proteasome pathway (UPP) is particularly impor-
tant, with the assistance of caspase-3 [23]. Importantly, the
insulin signaling pathway activates a number of signaling
molecules that overlap with the UPP [24], as illustrated in
Fig. 1. Binding of insulin to its receptor activates
phosphatidylinositol 3-kinase (PI3K) and Akt. The activa-
tion of Akt has been linked with suppression of FOXO and
caspase-3 activity, as well as decreasing mRNA expression
of atrogin-1 and MuRF-1, two important E3 enzymes in the
UPP. However, when the activity of PI3K is decreased, as it
is in cancer cachexia and other states of insulin resistance,
Fig. 1 Overlap between insulin signaling and ubiquitin–proteasome
pathways in insulin sensitive and insulin resistant states. In insulin
sensitive states (a), the binding of insulin to its receptor results in an
increase in PI3K activity, which increases the phosphorylation of
Akt. pAkt exerts inhibitory control over FoxO, which decreases
transcription of Atrogin-1, MURF-1, and MAFbx, and caspase-3. This
cascade results in decreased proteolytic activity. In contrast, in insulin-
resistant states (b), PI3K activity is decreased, leading to decreased
phosphorylation of Akt. Lower levels of pAkt release the inhibition of
FoxO and caspase-3, resulting in increased proteolytic activity
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the expression of components of the UPP is increased [24].
It is through this pathway that insulin is able to control
muscle protein degradation and one mechanism through
which insulin resistance can result in increased protein
degradation and the wasting of skeletal muscle.
3 The role of insulin resistance in cancer cachexia
Historically, insulin resistance has been classified as a
consequence of muscle wasting during cancer cachexia.
However, given insulin’s role in the maintenance of skeletal
muscle, insulin resistance should be considered as a
mechanism that contributes to the progression of muscle
wasting during cancer cachexia.
3.1 Insulin resistance is present during cancer cachexia:
Human subjects
The earliest known metabolic abnormality associated with
cancer was glucose intolerance [25]. In 1956, Glickman
and Rawson observed that approximately 37% of over 600
cancer patients exhibited “diabetic” glucose tolerance
curves, with a blunted insulin response to a standard dose
of glucose. This was the first large-scale study to
document specific metabolic effects of cancer in the
human population [26]. Since this time, additional studies
have observed the presence of insulin resistance in patients
with various types of tumors, as demonstrated by impaired
glucose tolerance [27–33] and decreased insulin sensitivity
[28, 29, 32].
Indirect evidence also suggests that alterations in glucose
tolerance are associated with the symptoms of cachexia in
cancer patients. Increased glucose production has been
observed in lung cancer patients, who also present with
increased rates of whole body protein turnover [30]. At
least a portion of this increased rate of protein turnover was
occurring within skeletal muscle, as these patients experi-
enced increased excretion of 3-methyhistidine, a marker of
skeletal muscle protein degradation [30]. Additional epide-
miological evidence suggests that glucose intolerance is
associated with an increased risk of cancer mortality [34].
For every 50 mg/dL increase in blood glucose levels,
individuals surveyed as part of the NHANES III dataset
increased their risk of cancer mortality by 22%.
When cachectic cancer patients, who present with
anorexia, weight loss, and muscle wasting, were compared
to non-cachectic patients and healthy controls by Jasani and
colleagues [28], an interesting pattern emerged. Non-
cachectic cancer patients exhibited a lower rate of glucose
uptake than healthy controls. However, cachectic cancer
patients exhibited significantly decreased rate of glucose
uptake compared to both healthy controls and the well-
nourished cancer patients [28]. While the non-cachectic
cancer patients had poor glucose uptake, it was greater than
that of the cachectic cancer patients, suggesting that an
increasing severity of glucose intolerance could be involved
in the development of cachexia.
Additional evidence suggests that impairments in oral and
intravenous glucose tolerance may be present in cancer
patients prior to the development of significant cachexia
symptoms [31]. In sarcoma patients without a significant
degree of weight loss (weight loss <5% of stable body
weight), intravenous glucose tolerance tests revealed signif-
icantly impaired glucose tolerance, as compared to healthy
controls. Interestingly, among the cancer patients in this
study, those that maintained a lower body weight showed
significantly reduced glucose tolerance as compared to
patients with a higher body weight [31], suggesting the
possibility that a lower maintenance weight may be a result
of decreased insulin sensitivity in these patients. The authors
conclude that glucose intolerance and accompanying insulin
resistance may play a role in the development of cachexia
symptoms, and is not merely a result of cachexia itself.
However, it is unknown whether either group of cancer
patients later developed cachexia symptoms, making the
authors’ conclusions somewhat premature.
Taken together, these data support the involvement of
insulin resistance in the development of muscle wasting in
patients with cancer cachexia. Additional experimental evi-
dence from animal models offers further support for this
hypothesis.
3.2 Insulin resistance is present during cancer cachexia:
Animal models
Insulin resistance is a common feature of multiple animal
models of cancer cachexia, including the Walker 256
carcinoma and colon-26 adenocarcinoma [35–40]. In
pancreatic islets of Langerhans isolated from rats bearing
the Walker 256 carcinoma, insulin secretion is decreased in
response to glucose stimulation, as compared to control
islets, indicating impaired insulin sensitivity [36]. In
addition, despite decreased blood glucose levels in colon-
26 adenocarcinoma-bearing mice, insulin sensitivity is
decreased as compared to non-tumor-bearing controls, as
indicated by in vivo insulin tolerance testing [39]. Impor-
tantly, structural changes in pancreatic islets have not been
observed, indicating that this decrease in insulin sensitivity
is not caused by structural abnormality, but instead by
deficits in insulin signaling [37].
Only one study directly examines the connection
between insulin resistance and the onset of cancer cachexia
[39]. By using an insulin tolerance test, Asp and colleagues
demonstrated that tumor-bearing mice exhibited a signifi-
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of insulin, as compared to non-tumor-bearing controls, prior
to the onset of significant weight loss. The authors assert
that their results support a causal role for insulin resistance
in the development of cancer cachexia [39]. However, the
researchers failed to measure body composition near the
time when reduced insulin sensitivity was observed.
Therefore, it is unknown whether insulin resistance was
actually present prior to the onset of cachexia or if some
muscle wasting was present prior to the onset of insulin
resistance. Despite this limitation, these results support the
hypothesis that insulin resistance may contribute to the
development of cancer cachexia in animal models.
3.3 Treatment with insulin and insulin sensitizers improves
cachexia symptoms
Given the involvement of insulin in the regulation of
skeletal muscle mass and the presence of insulin resistance
during cancer cachexia, treatment strategies that utilize the
insulin signaling system have begun to be explored.
Evidence suggests that these treatments have a positive
impact on patient outcomes and cachexia symptoms.
Lundholm and colleagues have observed improvements
in cachectic cancer patients following the administration of
insulin [41]. Importantly, these patients had reduced insulin
sensitivity but were not fully unresponsive to endogenous
insulin. When a small dose of exogenous insulin (0.11 U/kg
body weight) was administered daily to cachectic cancer
patients, increased body weight and caloric intake were
observed. These changes lead to increased survival time
and increased quality of life in insulin-treated patients,
without having a stimulating effect on tumor growth [41].
These data demonstrate that insulin treatment may have
beneficial effects in cachectic cancer patients. However, it
is important to recognize that the sample population
demonstrated some degree of insulin sensitivity. If the
subjects exhibited a greater degree of insulin resistance,
insulin treatment may not have produced the same effect.
Additional evidence from animal models of cachexia
supports these findings. However, due to differences in the
models utilized, results are mixed with regards to the
effectiveness of insulin treatment in cancer cachexia and
may be related to the degree of insulin sensitivity exhibited.
Animals implanted with Walker 256 tumors show improve-
ment in cachectic symptoms with daily insulin administra-
tion, including increased body weight and decreased tumor
mass [42–44]. Similar results have been observed in other
cancer cachexia models [45, 46]. In contrast, treatment with
exogenous insulin failed to have any effect on cachexia-
related parameters in mice inoculated with colon-26
adenocarcinoma [47]. It is possible that insulin resistance
is more complete in these animals than in other models.
This is supported by the fact that the administration of
insulin also had no effect on blood glucose levels in the
colon-26 tumor-bearing animals [47].
While insulin treatment fails to improve cancer cachexia
symptoms in colon-26 adenocarcinoma, Asp and colleagues
demonstrated the potential of an insulin-sensitizing agent to
prevent the development of muscle wasting in this model of
cancer cachexia. Following daily treatment with the
thiazolidinedione (TZD) rosiglitazone (0.3 μL per gram of
body weight, I.P), tumor-bearing mice did not experience
weight loss or a decrease in muscle mass as compared to
non-tumor-bearing controls. In addition, the TZD-treated
animals demonstrated normal insulin sensitivity, with a
significantly greater insulin-stimulated glucose response as
compared to PBS-treated tumor-bearing mice [39].
The utility of these treatments within the larger human
population is still under investigation. However, evidence
suggests that the insulin signaling pathway may be utilized
with some success in the treatment of cancer cachexia.
4 Potential treatment strategies
While the administration of insulin may ameliorate cachexia
symptoms in some patients and animal models, the effect is
notuniversal.Inaddition,manyofthese experimentshavenot
examined the effect of insulin on skeletal muscle mass.
However,treatmentsthatmoredirectlyaffectinsulinsignaling
hold promise as useful treatment strategies. While still in the
early stages of testing in individuals with and animal models
of cancer cachexia, these agents, including metformin,
thiazolidinediones, and β2-adrenoceptor agonists, demon-
strate a preliminary ability to increase muscle mass in
catabolic states through the activation of components of the
insulin signaling pathway. These treatment strategies are
highlighted in Table 1.
Metformin is a biguanide drug that was originally
developed for the treatment of insulin resistance associated
with type II diabetes mellitus. Metformin has been shown
to increase muscle cell insulin sensitivity [48] and to
reverse muscle wasting in a number of catabolic states,
including type II diabetes [49], polycystic ovary syndrome
(PCOS) [50], and CHF [51]. The effect of metformin on
muscle wasting appears to be regulated, in part, through its
ability to increase activity of AMP-activated protein kinase
(AMPK) in muscle cells [49]. An increase in AMPK
activity leads to increased glucose transporter 4 (GLUT4)
activity to increase skeletal muscle glucose uptake [52].
Additionally, metformin increases PI3K activity in patients
with type II diabetes and PCOS [53]. The use of metformin
in cancer cachexia has yet to be investigated fully, and
deserves attention, given its effectiveness in other catabolic
conditions.
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the treatment of patients with type II diabetes and have
proven effective in reversing insulin resistance in this
population [54], may offer a treatment path. While these
insulin sensitizers stimulate peroxisome-proliferator-
activated receptor γ, a nuclear transcription factor [54],
they also appear to have effects on insulin receptor
signaling [55]. In subjects with type II diabetes, treatment
with the TZD rosiglitazone decreased hepatic glucose
output and enhanced pancreatic β-cell function. In addition,
rosiglitazone-treated subjects exhibit increased insulin-
stimulated tyrosine phosphorylation of insulin receptor
substrate-1 (IRS-1) and increased PI3K activity [56].
Similar results have been observed in patients with CHF
[51]. The ability of this type of drug to increase insulin
sensitivity through alterations in a pathway that overlaps
with those involved in muscle proteolysis is intriguing. In
addition, Asp and colleagues observed that chronic admin-
istration of rosiglitazone prevented muscle wasting associ-
ated with cancer cachexia in mice implanted with the colon-
26 adenocarcinoma [39]. Due to their insulin-sensitizing
effects and their ability to act directly on skeletal muscle
tissue [56], the use of TZDs in the treatment of muscle
wasting during cancer cachexia should be investigated
further.
In addition, agonists of β2-adrenoceptors, such as
clenbuterol, albutamol, and calmeterol, have shown prom-
ise in increasing skeletal muscle mass in animal models of
type II diabetes and cancer cachexia [9, 11, 57–59].
Although this class of drugs has no effect on body weight
or caloric intake [58], they demonstrate the remarkable
ability to repartition nutrients, such that muscle mass
increases preferentially over fat mass [59]. To reverse
muscle wasting, these drugs appear to decrease protein
degradation by inhibiting caspase-3, decreasing proteaso-
mal activity, and reducing expression of various UPP-
related genes [60]. In addition, clenbuterol improves insulin
sensitivity through increases in GLUT4 and PI3K activity
[59, 61]. Taken together, these data demonstrate the ability
of a β2-adrenoceptor agonist to reduce muscle wasting in
cancer cachexia, through a mechanism involving the UPP,
as well as increase insulin sensitivity in insulin-resistant
states.
Overall, metformin, TZDs, and β2-adrenoceptor ago-
nists have been observed to improve muscle insulin
resistance in catabolic conditions by utilizing elements of
Table 1 Potential treatment options in cancer cachexia
Treatment Mechanism of action Effective in treating
MW associated with
References
Metformin Decreased hyperinsulinemia, increased insulin sensitivity in muscle,
increased PI3K and AMPK activity
DMII, PCOS, CHF 49, 53
TZDs PPAR-γ agonist, increased GLUT4, increased PI3K and AMPK activity DMII, CHF, CC-A
a 39, 51, 54, 56
β2-adrenoceptor agonists Increased GLUT4, increased PI3K activity, inhibition of caspase-3 DMII, CC-A
a 9, 11, 57, 62
Treatments, which utilize mechanisms related to the insulin signaling pathway, were found to be effective in treating muscle wasting associated
with chronic disease
TZDs Thiazolidinedione drugs, MW Muscle wasting, DMII Type II diabetes mellitus, PCOS Polycystic ovary syndrome, CHF Congestive heart
failure, CC-A Cancer cachexia in animal models
aNot tested in all animal models
Table 2 Future directions for
research
Suggestions for future research
regarding the relationship
between insulin resistance and
cancer cachexia
TZDs Thiazolidinedione drugs
Insulin resistance in animal models of cancer cachexia
Progression of insulin resistance during development of muscle wasting
Comparison of insulin resistance across animal models of cachexia
Effect of pre-existing insulin resistance on progression of cancer cachexia
Cause(s) of insulin resistance in animal models of cancer cachexia
Insulin resistance in human subjects with cancer cachexia
Epidemiological studies of cachexia incidence in insulin resistant individuals with cancer
Prospective measurement of insulin resistance and muscle status in individuals with cancer
Cause(s) of insulin resistance in individuals with cancer
Potential treatment options
Analysis of the effects of insulin sensitizers on skeletal muscle mass in animal models and human subjects
Effect of β2-adrenoceptor agonists on insulin sensitivity in animals models
Effect of TZDs on existing muscle wasting in animal models
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regulation of muscle mass. Given the effectiveness of
insulin-sensitizing treatments in other catabolic condi-
tions, the use of such treatments in patients with cancer
cachexia warrants significant attention. In particular, their
utility to reverse or prevent muscle wasting in cancer
cachexia may prove particularly important in patient
outcomes.
5 Conclusions and future directions
Available evidence suggests that insulin resistance may
play a role in the development of muscle wasting during
cancer cachexia. However, further research is necessary
before this knowledge can be effectively applied to the
treatment and prevention of cachexia in individuals with
cancer. A number of recommended future research direc-
tions are highlighted in Table 2.
This area of research has important potential implica-
tions for the clinical community. Currently, no evidence-
based treatments are available for the treatment of cancer
cachexia [11, 57]. Translational research is desperately
needed in this area to determine the mechanisms
through which cancer cachexia develops, as well as
how these mechanisms may be exploited to prevent and
treat cachexia symptoms in human cancer patients.
Insulin resistance is easily screened for in a variety of
healthcare settings and recent advances have allowed for
better treatment of this condition in many individuals
[62]. If insulin resistance could be utilized as an early
signal of the development of cancer cachexia, the
treatment of this metabolic abnormality could have the
potential to prevent the development of cachexia symp-
toms and have a profound impact on morbidity and
mortality in cancer patients.
Acknowledgments This work was supported by National Institutes
of Health DK078654 (KPK) and by the National Institutes of Health,
National Cancer Institute R25CA128770 (D. Teegarden) Cancer
Prevention Internship Program (MAH) administered by the
Oncological Sciences Center and the Discovery Learning Research
Center at Purdue University. The authors would like to thank Dr.
Terry Powley and Dr. Terry Davidson for their comments and
assistance. All authors of this manuscript comply with the
guidelines of ethical authorship and publishing in the Journal of
Cachexia, Sarcopenia and Muscle [63].
Conflict of interest The authors declare that they have no conflict of
interest
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Tisdale MJ. Biology of cachexia. J Natl Cancer Inst. 1997;89:1763–
73.
2. Kolter DP. Cachexia. Ann Intern Med. 2000;133:622–34.
3. Argiles JM, Alvarez B, Lopez-Soriano FJ. The metabolic basis of
cancer cachexia. Med Res Rev. 1997;17:477–98.
4. Tisdale MJ. Wasting in cancer. J Nutr. 1999;129:243S–6S.
5. Baracos VE. Hypercatabolism and hypermetabolism in wasting
states. Curr Opin Clin Nutr Metab Care. 2002;5:237–9.
6. Gordon JN, Green SR, Goggin PM. Cancer cachexia. Q J Med.
2005;98:779–88.
7. Coats AJS. Treatment goals. In: Hofbauer KG, Anker SD, Inui A,
Nicholson JR, editors. Pharmacotherapy of cachexia. Boca Raton,
FL: CRC Press; 2006. p. 261–6.
8. Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer.
2002;2:862–71.
9. Inui A. Cancer anorexia-cachexia syndrome: current issues in
research and management. CA Cancer J Clin. 2002;52:72–91.
10. Winkler MF. Body composition changes in cancer cachexia: are
they reversible? Top Clin Nutr. 2004;19:85–94.
11. Mantovani G, Maccios A, Massa E, Madeddu C. Managing
cancer-related anorexia/cachexia. Drugs. 2001;61:499–514.
12. Cahill GF, Aoki EE, Brennan MF, Muller WA. Insulin and muscle
amino acid balance. Proc Nutr Soc. 1972;31:233–8.
13. Louard RJ, Fryburg DA, Gelfand RA, Barrett EJ. Insulin
sensitivity of protein and glucose metabolism in human forearm
skeletal muscle. J Clin Invest. 1992;90:2348–54.
14. Gelfand RA, Barrett EJ. Effect of physiologic hyperinsulinemia
on skeletal muscle protein synthesis and breakdown in man. J Clin
Invest. 1987;80:1–6.
15. Biolo G, Wolfe RR. Insulin action on protein metabolism.
Baillieres Clin Endocrinol Metab. 1993;7:989–1005.
16. Wing SS, The UPS. In diabetes and obesity. BMC Biochem.
2003;9:56.
17. Wang A, Hu Z, Hu J, Du J, Mitch WE. Insulin resistance
accelerates muscle protein degradation: activation of the ubiquitin-
proteasome pathway by defects in muscle cell signaling. Endocrinol.
2006;147:4160–8.
18. Price SR, Bailey JL, Wang X, Jurkovitz C, England BK, Ding X,
Phillips LS. Muscle wasting in insulinopenic rats results from
activation of the ATP-dependent ubiquitin-proteasome proteolytic
pathway by a mechanism involving gene transcription. J Clin
Invest. 1996;98:1703–8.
19. Mitch WE, Bailey JL, Wang X, Jurkovitz C, Newby D, Price SR.
Evaluation of signals activating ubiquitin-proteasome proteolysis
in a model of muscle wasting. Am J Physiol Cell Physiol.
1999;276:C1132–8.
20. Hu J, Klein JD, Du J, Wang XH. Cardiac muscle protein catabolism
in diabetes mellitus: activation of the ubiquitin-proteasome
system by insulin deficiency. Endocrinol. 2008;149:5384–90.
21. Kino T, Mirani M, Alesci S, Chrousos GP. AIDS-related lipodys-
trophy/insulin resistance syndrome. Horm Metab Res. 2003;35:129–
36.
22. Coats AJS, Anker S. Insulin resistance in chronic heart failure. J
Cardiovasc Pharmacol. 2000;35:S9–S14.
23. Lecker SH, Solomon V, Mitch WE, Goldberg AL. Muscle protein
breakdown and the critical role of the ubiquitin-proteasome
pathway in normal and disease states. J Nutr. 1999;129:227S–
37S.
24. Lecker SH, Goldberg AL, Mitch WE. Protein degradation by the
ubiquitin-proteasome pathway in normal and disease states. J Am
Soc Nephrol. 2006;17:1807–19.
25. Rohdenburg GL, Bernard A, Krehbiel O. Sugar tolerance in
cancer. JAMA. 1919;72:1528–30.
10 J Cachexia Sarcopenia Muscle (2012) 3:5–1126. Glickman AS, Rawson RW. Diabetes and altered carbohydrate
metabolism in patients with cancer. Cancer. 1956;9:1127–34.
27. Holroyde CP, Gabuzda TG, Putnam RC, Paul P, Reichard GA.
Altered glucose metabolism in metastatic cancer. Cancer Res.
1975;35:3710–4.
28. Jasani B, Donaldson LJ, Ratcliffe JG, Sokhi GS. Mechanism of
impaired glucose tolerance in patients with neoplasia. Br J Cancer.
1978;38:287–92.
29. Lundholm K, Holm G, Schersten T. Insulin resistance in patients
with cancer. Cancer Res. 1978;38:4665–70.
30. Heber D, Chiebowski RT, Ishibashi DE, Herrold JN, Black JB.
Abnormalities in glucose and protein metabolism in noncachectic
lung cancer patients. Cancer Res. 1982;42:4815–9.
31. Norton JA, Maher M, Wesley R, White D, Brennan MF. Glucose
intolerance in sarcoma patients. Cancer. 1984;54:3022–7.
32. Tayek JA. A review of cancer cachexia and abnormal glucose
metabolism in humans with cancer. J Am Coll Nutr. 1992;11:445–
56.
33. Yoshikawa T, Noguchi Y, Doi C, Makino T, Okamoto T,
Matsumoto A. Insulin resistance was connected with the
alterations of substrate utilization in patients with cancer. Cancer
Lett. 1999;141:93–8.
34. Parekh N, Lin Y, Hayes RB, Albu JB, Lu-Yao GL. Longitudinal
associations of blood markers of insulin and glucose metabolism
and cancer mortality in the third National Health and Nutrition
Examination Survey. Cancer Cause Control. 2010;21:631–42.
35. Guaitani A, Recchia M, Carli M, Rocchetti M, Bartosek I,
Garattini S. Walker carcinoma 256: a model for studies on tumor-
induced anorexia and cachexia. Oncol. 1982;39:173–8.
36. Fernandes LC, Machado UF, Nogueira CR, Carpinelli AR, Curi
R. Insulin secretion in Walker 256 tumor cachexia. Am J Physiol
Endocrinol Metab. 1990;258:E1033–6.
37. el Razi Neto SER, Zorn TMT, Curi R, Carpinelli AR. Impairment
of insulin secretion in pancreatic islets isolated from Walker 256
tumor-bearing rats. Am J Physiol Cell Physiol. 1996;271:C804–9.
38. Tanaka Y, Eda H, Tanaka T, Udagawa T, Ishikawa T, Horii I,
Ishitsuka H, Kataoka T, et al. Experimental cancer cachexia
induced by transplantable colon 26 adenocarcinoma in mice.
Cancer Res. 1990;50:2290–5.
39. Asp ML, Tian M, Wendel AA, Belury MA. Evidence for the
contribution of insulin resistance to the development of cachexia
in tumor-bearing mice. Int J Cancer. 2009;126:756–63.
40. Lazarus DD, Destree AT, Mazzola LM, McCormack TA, Dick
LR, Xu B, Huang JQ, Pierce JW, et al. A new model of cancer
cachexia: contribution of the ubiquitin-proteasome pathway. Am J
Physiol Endocrinol Metab. 1999;277:E332–41.
41. Lundholm K, Korner U, Gunnebo L, Sixt-Ammilon P, Pouladiun
M, Daneryd P, Bosaeus I. Insulin treatment in cancer cachexia:
effects on survival, metabolism, and physical functioning. Clin
Cancer Res. 2007;13:2699–706.
42. Fernandes LC, Carpinelli AR, Hell NS, Curi R. Improvement of
cancer cachexia and decrease of Walker 256 tumorgrowth by insulin
administration in rats. Cancer Ther Control. 1991;1:259–68.
43. Fernandes LC, Curi R. Reversion of Walker 256 tumor cachexia
byinsulintreatment: possible mechanisms involved and perspectives
for future research. Endocr Relat Cancer. 1997;4:465–74.
44. Piffar PM, Fernandez R, Tchaikovski O, Hirabara SM, Folador A,
Pinto GJ, Jakobi S, Gobbo-Bordon D, et al. Naproxen, clenbu-
terol, and insulin administration ameliorates cancer cachexia and
reduce tumor growth in Walker 256 tumor-bearing rats. Cancer
Lett. 2003;201:139–48.
45. Moley JF, Morrison SD, Norton JA. Insulin reversal of cancer
cachexia in rats. Cancer Res. 1985;45:4925–31.
46. Moley JF, Morrison SD, Gorschboth CM, Norton JA. Body
composition changes in rats with experimental cancer cachexia:
improvement with exogenous insulin. Cancer Res. 1988;48:2784–7.
47. LazarusDD,KambayashiT,LowrySF,StrassmannG.Thelackofan
effect by insulin or insulin-like growth factor-1 in attenuating colon-
26 mediated cancer cachexia. Cancer Lett. 1996;103:71–7.
48. Komer R, Vrana A. Thiazolidinediones: tools for the research of
metabolic syndrome X. Physiol Res. 1998;47:215–25.
49. Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P,
Rooyackers O, Zhou G, Willimason JM, et al. Metformin
increased AMP-activated protein kinase activity in skeletal muscle
of subjects with type 2 diabetes. Diabetes. 2002;51:2074–81.
50. Diamanti-Kandarakis E, Christakou CD, Kandaraki E, Economou
FN. Metformin: an old medication of new fashion: evolving new
molecular mechanisms and clinical implications in polycystic
ovary syndrome. Eu J Endocrinol. 2010;162:193–212.
51. Wong AKF, al Zadjali MA, Choy AJ, Lang CC. Insulin resistance:
a potential new target for therapy in patients with heart failure.
Cardiovasc Ther. 2008;26:203–13.
52. Towler MC, Hardie DG. AMP-activated protein kinase in
metabolic control and insulin signaling. Circ Res. 2007;100:328–
41.
53. Diamanti-Kandarakis E, Economou F, Palimeri S, Christakou C.
Metformin in polycystic ovary syndrome. Ann N Y Acad Sci.
2010;1205:192–8.
54. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004;351:1106–
18.
55. Miyazaki Y, He H, Mandarino LJ, DeFronzo RA. Rosiglitazone
improves downstream insulin receptor signaling in type 2 diabetic
patients. Diabetes. 2003;52:1943–50.
56. Kintscher U, Law RE. PPARγ-mediated insulin sensitization: the
importance of fat versus muscle. Am J Physiol Endocrinol Metab.
2005;288:E287–91.
57. Gagnon B, Bruera E. A review of the drug treatment of cachexia
associated with cancer. Drugs. 1998;55:675–88.
58. Lambert CP, Uc EY, Evans WJ. β2-adrenergic agonists in the
treatment of muscle atrophy. In: Hofbauer KG, Anker SD, Inui A,
Nicholson JR, editors. Pharmacotherapy of cachexia. Boca Raton,
FL: CRC Press; 2006. p. 3311–24.
59. Castle A, Yaspelkis BB, Kuo C, Ivy JL. Attenuation of insulin
resistance by chronic β2-adrenergic agonist treatment: possible
muscle specific contributions. Life Sci. 2001;69:599–611.
60. Busquet S, Figueras MT, Fuster G, Almendro V, Moore-Carraso
R, Ametller E, Argiles JM, Lopez-Soriano FJ. Anticachectic
effects of formoterol: a drug for potential treatment of muscle
wasting. Cancer Res. 2004;64:6725–31.
61. Nevzorova J, Evans BA, Bengtsson T, Summers RJ. Multiple
signaling pathways involved in β2-adrenoceptor-mediated glucose
uptake in rat skeletal muscle cells. Br J Pharmacol. 2006;147:446–54.
62. Matthael S, Stumvoli M, Kellerer M, Haring H. Pathophysiology
and pharmacological treatment of insulin resistance. Endocr Rev.
2000;21:585–618.
63. vonHaehlingS,MorleyJE,CoatsAJS,AnkerSD.Ethicalguidelines
for authorship and publishing in the Journal of Cachexia, Sarcope-
nia and Muscle. J Cachex Sarcopenia Muscle. 2010;1:7–8.
J Cachexia Sarcopenia Muscle (2012) 3:5–11 11